Skip to main content

CVS pushes further into generic drugs with Sandoz partnership for new discount Humira

CVS is looking to strengthen its foothold in the biosimilars market, which is expected to grow to $100 billion over the next six years.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.